Article ; Online: Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-19.
Pulmonary pharmacology & therapeutics
2021 Volume 70, Page(s) 102069
Abstract: ... in close contact with patients with COVID-19.: Method: In this quasi-trial study, we prescribed HCQ ... for 7 days to all people who had close contact with a patient with COVID-19. All contacts underwent ... An in vitro study showed that hydroxychloroquine (HCQ) has a prophylactic effect against COVID-19 due ...
| Abstract | Introduction: The coronavirus disease 2019 (COVID-19) pandemic has caused significant mortality worldwide. The disease attacks the lung tissue and may lead to acute respiratory distress syndrome. An in vitro study showed that hydroxychloroquine (HCQ) has a prophylactic effect against COVID-19 due to its anti-inflammatory effects. The present study aimed to evaluate the prophylactic effect of HCQ on individuals in close contact with patients with COVID-19. Method: In this quasi-trial study, we prescribed HCQ for 7 days to all people who had close contact with a patient with COVID-19. All contacts underwent a nasal swab in two steps, and those positive for COVID-19 were excluded from the study. After 14 days of follow-up, the clinical and laboratory manifestations of COVID-19 were evaluated. Results: A total of 113 participants completed the study. The HCQ group comprised 51 (45.13%) contacts, and 62 (54.86%) contacts were allocated to the control group. According to the results of clinical examination and real-time polymerase chain reaction test, 8 (12.90%) contacts in the control group were reported to have contracted COVID-19. In the HCQ group, 7 (13.72%) contacts were confirmed to have contracted COVID-19. There was no relationship between HCQ use and age, sex, underlying disorders, and laboratory data (all p > 0.05). In terms of HCQ side effects, five participants experienced gastrointestinal and cutaneous side effects that subsided on discontinuation of HCQ. Conclusion: The current study showed that HCQ had no prophylactic effect with regard to COVID-19 prevention. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | COVID-19/drug therapy ; Humans ; Hydroxychloroquine ; SARS-CoV-2 ; Treatment Outcome | |||||
| Chemical Substances | Hydroxychloroquine (4QWG6N8QKH) | |||||
| Language | English | |||||
| Publishing date | 2021-08-10 | |||||
| Publishing country | England | |||||
| Document type | Journal Article ; Research Support, Non-U.S. Gov't | |||||
| ZDB-ID | 1399707-5 | |||||
| ISSN | 1522-9629 ; 1094-5539 | |||||
| ISSN (online) | 1522-9629 | |||||
| ISSN | 1094-5539 | |||||
| DOI | 10.1016/j.pupt.2021.102069 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2389: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.